All In Biotech

Drug Trial Radar · NCT07643766

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 29, 2026

Primary completion

Dec 2027

Study completion May 2028

Sponsor

Lead sponsor
Enveda TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive study treatment, and complete scheduled assessments of disease activity, symptoms, quality of life, safety, pharmacokinetics, and biomarker responses.

Conditions

  • Atopic Dermatitis

Interventions

  • ENV-294Drug

    ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks.

  • PlaceboOther

    Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in Eczema Area and Severity Index (EASI) scoreTime frame: Baseline to Week 12

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Enveda Investigative Site

    Encinitas, California · Recruiting

  • Enveda Investigative Site

    Los Angeles, California · Recruiting

  • Enveda Investigative Site

    Northridge, California · Recruiting

  • Enveda Investigative Site

    Boca Raton, Florida · Recruiting

  • Enveda Investigative Site

    Indianapolis, Indiana · Recruiting

  • Enveda Investigative Site

    Plainfield, Indiana · Recruiting

  • Enveda Investigative Site

    Dallas, Texas · Recruiting

  • Enveda Investigative Site

    San Antonio, Texas · Recruiting

  • Enveda Investigative Site

    Sugar Land, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.